Oculis (NASDAQ:OCS) Sees Strong Trading Volume

Oculis Holding AG (NASDAQ:OCS - Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 52,187 shares were traded during mid-day trading, an increase of 11% from the previous session's volume of 47,215 shares.The stock last traded at $13.25 and had previously closed at $12.73.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Robert W. Baird dropped their price objective on Oculis from $64.00 to $35.00 and set an "outperform" rating on the stock in a report on Tuesday, March 19th. Wedbush reissued an "outperform" rating and set a $29.00 price target on shares of Oculis in a report on Wednesday, March 6th. HC Wainwright lowered their price target on Oculis from $29.00 to $28.00 and set a "buy" rating on the stock in a report on Wednesday, April 24th. Finally, Chardan Capital restated a "buy" rating and issued a $30.00 price objective on shares of Oculis in a research report on Tuesday, March 19th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $29.14.

Oculis Price Performance

The stock's 50-day moving average price is $11.86 and its 200-day moving average price is $11.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.29 and a current ratio of 5.29.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.04. The company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.28 million. On average, analysts forecast that Oculis Holding AG will post -1.72 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of OCS. Wolverine Asset Management LLC acquired a new stake in shares of Oculis in the 3rd quarter valued at about $77,000. Compagnie Lombard Odier SCmA grew its position in shares of Oculis by 47.3% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company's stock valued at $1,053,000 after buying an additional 30,750 shares during the last quarter. abrdn plc bought a new stake in shares of Oculis during the 4th quarter valued at about $15,980,000. Finally, Searle & CO. bought a new stake in shares of Oculis during the 4th quarter valued at about $112,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.